Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is One Post you may want to place in your CVSI I-HubCap archives.
“That left me with two viable candidates with very similar valuation metrics. Both companies are well established in the industry and both have turned the corner to profitability. As of early June, both had very similar growth catalysts Forward PE estimates around 20. In the end, while I was drawn to the heart-melting story of Charlotte's Web Holdings (OTCQX: CWBHF) essentially curing five-year-old Charlotte Figi, I chose CV Science (OTCQX: CWBHF) as the best place for value investors to put their investment dollars. In the balance of this article, I will explain why.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150316507
https://www.gurufocus.com/news/921382/value-idea-contest-cv-sciences-a-value-stock-with-explosive-potential
CV Sciences was founded in Texas on December 9th, 2010 and it is astounding how much the company has changed since that time. CV Sciences, Inc. was initially incorporated under the name Foreclosure Solutions with the intention of selling realtor services to homebuyers interested in foreclosed properties. The company later changed its name to Cannavest Corp. in 2013 and eventually settled on the corporate name CV Sciences in 2016.
The company operates in two segments, consumer products, and specialty pharmaceutical. The consumer product division does the heavy lifting at this point with the PlusCBD brand offering 50 different products within its portfolio. The product line includes gummies, sprays, softgels, balms, drops, and capsules. While it hasn't contributed to profits yet, management has high hopes for the specialty pharmaceutical segment and expects the first contributor to be a cessation product for smokeless tobacco.
Financial Fortitude
Unlike many of its brethren in the marijuana/hemp industry, CV Sciences is on solid financial footing. Despite putting research and development dollars into the specialty pharmaceutical segment that have not yet impacted the top or bottom lines, the company is sitting on over $13 million in cash and has a current ratio of 2.97. Cash is up 300% on a year over year basis.
Data Source: CV Sciences Investor Relations
I like the fact that the company has been able to keep a clean balance sheet and a comfortable cash position amidst rapid growth. All indications are management has the ability to handle ongoing rapid growth in a financially disciplined manner.
Management
Joseph Dowling was appointed as Chief Executive Officer of the Company in May 2018. Dowling was promoted from the position of CFO, which he held since 2014. To be honest, this was initially a concern of mine.
The reason for my concern was that when the CBD industry started exploding, Charlotte's Web brought in a ringer in Deanie Elsner, the lady who ran Kellogg's $3 billion snack food segment. My initial reaction was that CV Sciences' decision to promote may put the company at a competitive disadvantage.
So far, Dowling has shown that he is no slouch and the stage does not appear too big for him. In fact, it was CV Sciences, not Charlotte's Web, that first signed a partnership agreement with a major grocery chain when they did so with Kroger in early June. When Elsner and Charlotte's Web secured an agreement of their own on July 29th, Dowling was not to be outdone. The very next day, Dowling expanded his initial agreement to include 1350 stores, up from the initial agreement including 945.
It appears Dowling, with 35 years of leadership experience, is up to the task and there will be more agreements to come. Prior to 2014, Mr. Dowling held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery from 2005 to 2013 where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance-building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. Mr. Dowling also served as a Managing Director at Citigroup, a global financial services firm.
Other key leaders include Joerg Grasser, CFO, and Michael Mona, COO. Mona is a co-founder of CV Sciences and importantly, has a decade of experience in hemp-based supply chain.
Valuation
This is where CV Sciences truly gets the nod, in my opinion. Analysts, including Roth Capital, are predicting EPS of $.11 this year and $.22 next year, giving the stock a Forward PE of 18. As of mid-June, these numbers were almost identical to those predicted for Charlotte's Web. Yet, since that time, despite having almost identical catalysts, Charlotte's Web has seen its stock skyrocket to the tune of a 65% gain while CV Sciences has actually pulled back, giving it a much friendlier valuation at present.
Interestingly, these EPS estimates were laid out before the Kroger deals, a development that puts PlusCBD on the shelves of 1350 grocery stores. While there are a lot of variables, it is hard to imagine that increasing store count by almost 40% in one quarter can do anything but help the top and bottom lines.
CVSI AND CWBHF SHARE PRICE CHANGE-LAST TWO MONTHS Data by YCharts
Associated Risks
Competition, of course, is the first risk. While there is a saying, "A rising tide lifts all boats", that saying is not always true. The CBD market is growing by leaps and bounds but not all companies will come out as winners. Right now, the CBD industry is highly fragmented with a few established publicly traded companies and a lot of private outfits trying to cash in. While CV Sciences is one of the two most established and profitable players, more competition is on the way. Some of these new entrants are likely to be larger in size with more resources to bring to battle.
More entrants into the CBD space will also mean competition on pricing and very likely some margin compression. That is part and parcel for any industry in an explosive growth phase. Margin compression is down the road a little bit and I am okay with it as long as healthy profit growth can continue, and I believe it can.
The second risk worth mentioning is regulation. Right now, the CBD industry is highly fragmented and highly unregulated. The current "anything goes" environment has gotten a lot of press recently and there are plenty of calls for tightening standards. It seems those calls are getting traction. The fact that the FDA held a hearing on May 31st makes it clear that the federal government is aware of the need for protecting consumers and ensuring some standard of quality. More recently, the FDA sent a letter to Curaleaf for marketing unapproved CBD products.
While increased oversight brings risk, I believe more regulation would actually be to the advantage of established players like CV Sciences. Let's remember that CV Sciences is not exactly hiding from the FDA. In fact, CV Sciences is currently actively engaged with the FDA in its specialty pharmaceutical efforts.
Finally, merger and acquisition activity is a wild card. Both Forbes and U.S. News and World Report have highlighted the advantages of strategic partnerships in the industry. CBD M&A activity has been quiet when compared to cannabis, but that could change with the current landscape of industry growth.
Looking Ahead
It is time to reiterate that the CBD space is an industry experiencing extremely rapid growth. While growth estimates vary wildly, the chart below represents the most conservative numbers I could find. A recent Forbes article predicted a $16 billion CBD market by 2025, up from approximately a $1 billion market today. Brightfield projects even more robust growth. Brightfield estimates that the CBD industry will grow 40-fold within four years and hit $22 billion by 2022.
Data Source: Statista
Company Growth
CV Sciences has certainly been active, maybe even aggressive, in trying to secure its share of industry growth. The company's revenue and gross profit both more than doubled from 2017 to 2018. The trend continues as Q1 of 2019 showed 97% YOY growth from the same quarter a year ago. In addition, the company has brought 9 new products to market this year and has 13 more new products in development for launch later in the year. Twenty-two new products represent a 44% increase in product portfolio in this year alone. Similar growth is seen in retail store count, where CV Sciences now has 4,900 retail locations carrying its products, up from 2200 at the end of 2018.
Source: CVSI Investor Presentation June 18, 2019
There are essentially three catalysts which will all but guarantee continued rapid growth in the near term. First of all, the company is keeping its foot on the gas by putting on more than 40 trade shows annually. Secondly, the Farm Bill of 2018 legalized the production of industrial hemp and sales of CBD derived from hemp. Finally, as mentioned above, CV Sciences is working hard to expand into the specialty pharmaceutical space and recently presented to the FDA as a step to getting the first cessation drug for smokeless tobacco to market in the next couple of years.
Conclusion
CV Sciences is not for the faint of heart. In fact, CV Sciences is somewhat of a feast or famine stock. As of a year ago, it was close to being a penny stock. However, with some assistance from the Farm Bill, the stock price floor has risen significantly since that time. In addition, the company is profitable and with a reputable auditor in Deloitte & Touche, you can trust the numbers.
Quarter Low High
Q1 2017 .36 .59
Q2 2017.59 .22 .41
Q3 2017 .21 .36
Q4 2017 .14 .68
Q1 2018 .38 .63
Q2 2018 .41 2.41
Q3 2018 1.60 7.13
Q4 2018 3.55 6.40
Stock Prices By Quarter Data Source: CV Sciences 10-K Chart by Author
CV Sciences does come with some risk but it also has a lot of catalysts. I am not afraid of M&A or increased regulation, as I view those as likely positives. The industry and company are growing rapidly and I doubt the Kroger deal is the last of its kind. If things go well, which I believe is likely, the stock could reasonably double or triple over the next three years. If you are a value investor and are interested in the CBD space, CV Sciences, at $4.05 a share, deserves a place on your investing radar.
for 30 days > July 16 > August 15
The mark is published in a book of all published trademarks before the U.S. Patent and Trademark Office known as the Official Gazette. Trademarks are published for opposition for 30 days. During this period any party wishing to object to the registration of the trademark may do so by filing a Notice of Opposition.
Date Description Proceeding Number
Jul. 16, 2019 OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul. 16, 2019 PUBLISHED FOR OPPOSITION
https://tsdr.uspto.gov/#caseNumber=88051019&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
CBD for pain relief: What the science says
https://www.cnet.com/news/cbd-for-pain-relief-what-the-science-says/
What Dr. Fang says Plus CBDOIL ™
is the “King of Pain” you understand. Wolf
CBD retailers, growers expand into new states
https://www.upi.com/Top_News/US/2019/08/03/CBD-retailers-growers-expand-into-new-states/8391564870877/
CBD retailers, growers expand into new states
The From AndY and Rich from the CVSY. Wolf
Value Idea Contest: CV Sciences - A Value Stock With Explosive Potential
https://www.gurufocus.com/news/921382/value-idea-contest-cv-sciences-a-value-stock-with-explosive-potential
California is on the brink of legalizing hemp-derived cannabidiol (“Hemp CBD”) in many products—well, sort of. The law at issue is Assembly Bill 228 (“AB-228”), and I’ve been writing about it since it was introduced in January 2019 (for my posts on it, see here, here, and here). As of today, it’s made its way through the California Assembly and most of the way through the California Senate with very little resistance. AB-228 is likely to pass soon, and because it is what’s called an “urgency” statute, will become immediately effective.
https://www.cannalawblog.com/california-is-poised-to-pass-a-landmark-hemp-cbd-law/
Since I started writing about AB-228, the bill has morphed a lot, and now actually has some teeth. Even if it passes though, Hemp CBD may not be completely legal in the Golden State. Here’s a brief explanation of what’s happened, and what’s at stake.
About a year ago, the California Department of Public Health’s (“CDPH”) released its now-infamous Hemp CBD FAQs, which take the position that Hemp CBD is illegal in basically all foods, beverages, and some other products (but note, there is not a single law or regulation on the books anywhere in the state that takes this position). The FAQs “outlawed” Hemp CBD based on the federal Controlled Substances Act (which as of December 20, 2018 and the passage of the 2018 Farm Bill no longer hemp illegal) and the fact that the federal Food and Drug Administration (“FDA”) did not allow the addition of Hemp CBD to the same products that are mentioned in the FAQs. (For a discussion of the FDA’s policy memos which claim that Hemp CBD is illegal, see here and here).
While the FAQs didn’t really cite California law (except to define foods, etc.) as the basis for enforcement, it’s come to light that the CDPH has been relying on the California Sherman Food, Drug, & Cosmetic Law (not to be confused with the federal Sherman Act, an antitrust law), to pull Hemp CBD products from retail and wholesale operations. The CA Sherman Law gives the CDPH authority over foods and beverages and allows them to target products that it deems “adulterated”. In a sense, the CA Sherman Law is a lot like the federal Food, Drug and Cosmetic Act that the FDA gets its authority from (hence all of the citations to FDA policy).
Originally, AB-228 was very narrow and only would have created a law saying that the mere addition of Hemp CBD to foods and cosmetics did not adulterate them. Over the last few months, in various committees, more and more things have been piled onto the bill. Here are some of the highlights of the current version:
Licensed cannabis companies wouldn’t be precluded from being in the hemp business;
Hemp products that are foods, beverages, or cosmetics would have some minimal labeling requirements;
Food manufacturers that make hemp products would be required to obtain certain registrations and would need to demonstrate that their hemp comes from a jurisdiction that has an “established and approved industrial hemp program” that meets all federal requirements for the sale and cultivation of hemp;
The CDPH wouldn’t be able to conclude that foods, beverages, or cosmetics are adulterated just because they contain CBD; and
Raw hemp products would need to undergo certain lab testing and get certificates of analysis prior to sale.
It’s clear that if AB-228 becomes law, it will be a huge victory for the burgeoning hemp industry across the state. But there are a few key issues that may still not wipe out the gray areas:
AB-228 does not change federal law. The California legislature has no power to modify federal law or policy. The FDA’s policy memos are not affected by California law. If sellers sell Hemp CBD foods, they may still draw the ire of the FDA—which is more likely if medical claims are made.
AB-228 does not require the CDPH to ignore federal law. Remember that the CDPH FAQs cited the FDA’s position. It is theoretically possible that the CDPH could continue to uphold the FAQs unless and until the FDA changes its mind. I think this is unlikely to happen, but in the hemp world, sometimes anything is possible.
AB-228 does not take away all grounds for enforcement from CDPH. If AB-228 passes, the addition of Hemp CBD to foods and cosmetics alone doesn’t render them adulterated. But that’s just scratching the surface. Other things could render them adulterated. The CDPH can also go after “misbranded” foods and other products. And, of course, there are tons of other product specific laws (e.g., Prop. 65) that may create problems for sellers of CBD goods.
In spite of these issues, if AB-228 passes it’ll create a lot of certainty for hemp businesses in California, where there previously wasn’t much. We’ll stay tuned on updates to this law and how it will affect the hemp industry in California, and as a whole.
Print:EmailTweetLikeLinkedIn
https://www.cannalawblog.com/california-is-poised-to-pass-a-landmark-hemp-cbd-law/
Here is the original International registration number 1264736. If you noticed, from the history they had to file in May after the FB Requirements.
Mark Image
Word Mark PLUS + CBDOIL
Goods and Services IC 003. US 001 004 006 050 051 052. G & S: Body care and toiletry products, namely, skin moisturizers containing CBD. FIRST USE: 20141231. FIRST USE IN COMMERCE: 20141231
IC 004. US 001 006 015. G & S: Hemp oil derived from hemp for use in the manufacture of a wide variety of goods, namely, body care and toiletry products, dietary and nutritional supplements, nutritional food additive for culinary purposes, beverages and food stuffs and clothing; all of the foregoing containing CBD. FIRST USE: 20111231. FIRST USE IN COMMERCE: 20141231
IC 005. US 006 018 044 046 051 052. G & S: Dietary and nutritional supplements; topical balms for analgesic purposes; nutrition supplements in capsule form and in liquid form; all of the foregoing containing CBD. FIRST USE: 20141231. FIRST USE IN COMMERCE: 20141231
IC 035. US 100 101 102. G & S: On-line retail store services in the field of dietary and nutritional supplements containing CBD, body care and toiletry products containing CBD; wholesale distributorship services featuring dietary and nutritional supplements containing CBD, body care and toiletry products containing CBD. FIRST USE: 20141231. FIRST USE IN COMMERCE: 20141231
Mark Drawing Code (3) DESIGN PLUS WORDS, LETTERS, AND/OR NUMBERS
Design Search Code 01.15.15 - Fire (flames), emanating from objects, words or numbers
24.17.06 - Plus symbol (+)
26.17.13 - Letters or words underlined and/or overlined by one or more strokes or lines ; Overlined words or letters ; Underlined words or letters
Serial Number 86522004
Filing Date February 2, 2015
Current Basis 1B
Original Filing Basis 1B
Published for Opposition March 29, 2016
International Registration Number 1264636
Owner (APPLICANT) CV SCIENCES, INC. CORPORATION DELAWARE 10070 Barnes Canyon Road, Suite 100 San Diego CALIFORNIA 92121
Assignment Recorded ASSIGNMENT RECORDED
Attorney of Record Rosie H. Kim
Disclaimer NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "CBD OIL" FOR CLASSES 1, 3, 4, 5, 29, 30, 35, 42 AND "PLUS" FOR CLASS 25 APART FROM THE MARK AS SHOWN
Description of Mark Color is not claimed as a feature of the mark. The mark consists of the word "PLUS" in small font above the "C" in "+CBDOIL" with the design of a flame above the "I"; "CBDOIL" is underlined.
Type of Mark TRADEMARK. SERVICE MARK
Register PRINCIPAL
Live/Dead Indicator LIVE
++*+*+***++++++++++++++++++++++++¥¥¥¥¥¥++++++
Prosecution History
Date Description Proceeding Number
May 21, 2019 STATEMENT OF USE PROCESSING COMPLETE 71034
May 20, 2019 USE AMENDMENT FILED 71034
May 20, 2019 TEAS STATEMENT OF USE RECEIVED
Nov. 27, 2018 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov. 26, 2018 EXTENSION 5 GRANTED 71034
Nov. 21, 2018 EXTENSION 5 FILED 71034
Nov. 21, 2018 TEAS EXTENSION RECEIVED
May 25, 2018 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 24, 2018 EXTENSION 4 GRANTED 71034
May 16, 2018 EXTENSION 4 FILED 71034
May 24, 2018 CASE ASSIGNED TO INTENT TO USE PARALEGAL 71034
May 16, 2018 TEAS EXTENSION RECEIVED
Apr. 17, 2018 APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED 88888
Apr. 17, 2018 TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov. 23, 2017 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov. 21, 2017 EXTENSION 3 GRANTED 98765
Nov. 21, 2017 EXTENSION 3 FILED 98765
Nov. 21, 2017 TEAS EXTENSION RECEIVED
Nov. 21, 2017 TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov. 20, 2017 ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov. 20, 2017 TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 26, 2017 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 24, 2017 EXTENSION 2 GRANTED 98765
May 24, 2017 EXTENSION 2 FILED 98765
May 24, 2017 TEAS EXTENSION RECEIVED
Feb. 15, 2017 ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb. 15, 2017 TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec. 08, 2016 NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec. 07, 2016 EXTENSION 1 GRANTED 81929
Nov. 18, 2016 EXTENSION 1 FILED 81929
Dec. 07, 2016 CASE ASSIGNED TO INTENT TO USE PARALEGAL 81929
Nov. 18, 2016 TEAS EXTENSION RECEIVED
May 24, 2016 NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar. 30, 2016 AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar. 29, 2016 OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar. 29, 2016 PUBLISHED FOR OPPOSITION
Mar. 09, 2016 NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb. 25, 2016 LAW OFFICE PUBLICATION REVIEW COMPLETED 68552
Feb. 18, 2016 APPROVED FOR PUB - PRINCIPAL REGISTER
Feb. 11, 2016 EXAMINER'S AMENDMENT ENTERED 68552
Feb. 11, 2016 NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED 6328
Feb. 11, 2016 EXAMINERS AMENDMENT E-MAILED 6328
Feb. 11, 2016 EXAMINERS AMENDMENT -WRITTEN 82107
Jan. 25, 2016 TEAS/EMAIL CORRESPONDENCE ENTERED 68552
Jan. 25, 2016 CORRESPONDENCE RECEIVED IN LAW OFFICE 68552
Jan. 21, 2016 ASSIGNED TO LIE 68552
Jan. 08, 2016 TEAS VOLUNTARY AMENDMENT RECEIVED
Jan. 06, 2016 PREVIOUS ALLOWANCE COUNT WITHDRAWN
Dec. 08, 2015 WITHDRAWN FROM PUB - OG REVIEW QUERY 99910
Nov. 05, 2015 APPROVED FOR PUB - PRINCIPAL REGISTER
Oct. 27, 2015 TEAS/EMAIL CORRESPONDENCE ENTERED 88889
Oct. 26, 2015 CORRESPONDENCE RECEIVED IN LAW OFFICE 88889
Oct. 26, 2015 TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun. 10, 2015 ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun. 10, 2015 TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr. 24, 2015 NOTIFICATION OF NON-FINAL ACTION E-MAILED 6325
Apr. 24, 2015 NON-FINAL ACTION E-MAILED 6325
Apr. 24, 2015 NON-FINAL ACTION WRITTEN 82107
Apr. 17, 2015 ASSIGNED TO EXAMINER 82107
Mar. 10, 2015 ASSIGNED TO EXAMINER 73355
Mar. 03, 2015 APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED 88889
Mar. 03, 2015 TEAS VOLUNTARY AMENDMENT RECEIVED
Feb. 18, 2015 ASSIGNED TO EXAMINER 82107
Feb. 12, 2015 NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb. 11, 2015 NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Feb. 05, 2015 NEW APPLICATION ENTERED IN TRAM
TM Staff and Location Information
Dr. J. I just found this registration. CVSI applied for three Plus CBDOIL trademarks. They are only interested in the one I posted prior. This one is the most important and is already protected and registered on the international market. They have registered both ways.
PLUS + CBD OIL The prior one I posted
The one I found today
PLUS + CBDOIL
Body care and toiletry products, namely, skin moisturizers containing CBD
International Class(es): 003 - Primary Class U.S Class(es): 001, 004, 006, 050, 051, 052
Class Status: ACTIVE
Basis: 1(b)
First Use: Dec. 31, 2014 Use in Commerce: Dec. 31, 2014
For: Hemp oil derived from hemp for use in the manufacture of a wide variety of goods, namely, body care and toiletry products, dietary and nutritional supplements, nutritional food additive for culinary purposes, beverages and food stuffs and clothing; all of the foregoing containing CBD
International Class(es): 004 - Primary Class U.S Class(es): 001, 006, 015
Class Status: ACTIVE
Basis: 1(b)
First Use: Dec. 31, 2011 Use in Commerce: Dec. 31, 2014
For: Dietary and nutritional supplements; topical balms for analgesic purposes; nutrition supplements in capsule form and in liquid form; all of the foregoing containing CBD
International Class(es): 005 - Primary Class U.S Class(es): 006, 018, 044, 046, 051, 052
Class Status: ACTIVE
Basis: 1(b)
First Use: Dec. 31, 2014 Use in Commerce: Dec. 31, 2014
For: On-line retail store services in the field of dietary and nutritional supplements containing CBD, body care and toiletry products containing CBD; wholesale distributorship services featuring dietary and nutritional supplements containing CBD, body care and toiletry products containing CBD
International Class(es): 035 - Primary Class U.S Class(es): 100, 101, 102
Class Status: ACTIVE
Basis: 1(b)
First Use: Dec. 31, 2014 Use in Commerce: Dec. 31, 2014
Basis Information (Case Level)
https://tsdr.uspto.gov/#caseNumber=86522004&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
Their tradename is fine. Together or not. That is why they Seem to be not pursuing their Plus + Hemp Oil trademark.
https://tsdr.uspto.gov/#caseNumber=88051064&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
https://tsdr.uspto.gov/#caseNumber=88051019&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
According to Brightfield Group, the CBD market in the U.S. has grown over 700% in 2019.
The CBD industry is becoming much more saturated than it was before the passing of the U.S. Farm Bill late last year, with new products entering the market, threatening to take a slice of the CBD pie that the early producers of CBD have enjoyed until this time.
Nevertheless, the top 20 CBD companies still hold a majority of the even bigger pie that is CBD in the cannabis industry.
Brightfield Group listed the Top 5 CBD Companies that the research group says “continue to make a name for themselves” within the growing CBD market. Here’s what we know about these various companies:
https://www.greenmarketreport.com/brightfield-group-names-top-5-cbd-companies/
The Brand name is fine. They have underneath the brand name “Hemp Extract”. What I foresee in the near future is a label with their Trademark New Harvest ™ Along with Plus + CBD Oil. Dr. Fang would argue CBD In its natural state is a chemical not a drug. THC is a chemical not a drug. Nicotine is a chemical not a drug. Therefore, Hemp is not a drug and Tobacco is not a drug and Marijuana is falsely labeled a drug. The FDA should change their name to FDCA.. Wolf on steroids. Ahooooooo
You are right on in your opinion. This lady in my opinion left one scam to work another. I remember when she left for GB you understand. Imo Wolf
https://international-cdp.com/speaker/andrea-small-howard/
This is one of my kids I coached in Little League Baseball. Intimidation.ahooooooo Wolfie
The hot start cannabis companies enjoyed to 2019 fizzled out in July, and short sellers jumped at the opportunity to add to their bets that the trend will continue, according to a new report.
Last month, net short positions in the cannabis space increased by 7.2 million shares, or $169.7 million, according to data from market tracker S3 Analytics.
The cannabis company that saw the highest uptick in short activity in terms of dollar bets against it was Canopy Growth (CGC), which parted ways with its CEO Bruce Linton to start the month. In total, short sellers added an additional $69.6 million worth of Canopy shares to short positions, despite higher than average borrowing fees.
Canopy Growth saw short sellers pile on bets against the company in July. The $69 million worth of Canopy shares added to short positions in July was the largest for any cannabis company over the past month.
Canopy Growth saw short sellers pile on bets against the company in July. The $69 million worth of Canopy shares added to short positions in July was the largest for any cannabis company over the past month.
The fact that Canopy topped the list of cannabis shorts in July shouldn’t come as that big of a surprise, according to Morgan Paxhia, co-founder of the cannabis-focused Poseidon Asset Management, who told Yahoo Finance’s YFi PM that shorting some of the larger cannabis names can often be easier due to availability. Canopy is the largest cannabis company in the world by market cap.
However, Paxhia did challenge the notion that the same sentiment that sent Canopy shares down by about 20% in July would carry over to the rest of the year.
“In 2019, we’ve seen quite a shift in investor scrutiny over the sector,” he said. “Even into Canada’s federal legalization last October most of the industry was predominantly trading around the idea of pro-forma — what was the future promising, what were these next big catalysts unlocking growth? ... Now we’re beyond a lot of those initial catalysts, even though there’s still a lot of growth to go left in this industry.”
Weathering the shift in sentiment in the cannabis sector proved easier for the marijuana-focused Alternative Harvest ETF (MJ) which only fell by about 11% for the month.
‘A natural reaction’
Jason Wilson, a partner in the ETF, added that July seemed like more of a readjustment as investors weigh a longer than expected investing horizon as more cannabis companies push out their path to profitability.
“This is to me a natural reaction with the big price run up at the beginning of the year,” he said. “Through this whole correction we’ve seen more creation more shares coming into the fund, so generally speaking, investors seem to be looking at this as the market maturing, companies working through growing pains, execution pains, but they still have their eyes on the prize which is global expansion and the size that the global market will be in the next 10 to 15 years.”
Interestingly, cannabis companies have in large part traded together, but both Paxhia and Wilson agreed that could change as investors weigh execution and profitability more heavily moving forward. Updates to both will come in shortly as more cannabis companies gear up to report earnings, with Canopy updating investors mid-August.
GB SCIENCES FILES NOVEL PATENT APPLICATION FOR CHRONIC PAIN TREATMENTS BASED ON PROPRIETARY CANNABIS-DERIVED FORMULATIONS
https://gbsciences.com/2019/07/20/patent-app/
GB SCIENCES FILES NOVEL PATENT APPLICATION FOR CHRONIC PAIN TREATMENTS BASED ON PROPRIETARY CANNABIS-DERIVED FORMULATIONS
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.
LAS VEGAS, July 17, 2019/PR Newswire/– GB Sciences, Inc. (OTCQB: GBLX), through its subsidiary, GBS Global Biopharma, Inc. (“GBS”, Ottawa, CANADA), has filed a novel patent application to protect proprietary formulations for chronic pain based on new molecular docking simulations and functional assay data. New pain treatments are a vitally important area of research and development given the widespread rates of addiction and mortality tied to opioids. Opioid addiction affects 1.7 Million Americans, kills approximately 50,000 individuals per year, and has an emerging health economic burden of $78.5 billion per year. In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.
By combining functional testing and computational modeling, GBS has rationally designed complex mixtures of active ingredients from the cannabis plant through simultaneously inactivating or desensitizing several of the pain-sensing, Transient Receptor Potential (TRP) Superfamily members. These formulations have the potential for enhanced pain relief. This patent application seeks to protect these cannabinoid-containing complex mixtures and addresses GBS’ proprietary method for selecting cannabis-derived compounds based on data from high throughput screening assays, electrophysiology of the TRP channels, and molecular docking simulators.
Significantly, GBS and their research partners at Chaminade University are the first to model the putative TRPV1-binding sites of myrcene and cannabidiol, two of the active ingredients in their complex mixtures for chronic pain. They have used information on the molecular interactions within these TRPV1-binding pockets to discriminate between the potential pain-relieving benefits of other cannabis-based compounds in their initial cannabis-derived mixtures.
“Unlike others who are narrowly focused on using a very limited number of cannabinoids for the treatment of pain, we embraced the complexity of whole-plant cannabis extracts and then optimized these mixtures using both functional assays and computer modeling, which has allowed us to seek patent protection for groundbreaking chronic pain therapies,” said Chief Science Officer and Director, Dr. Andrea Small-Howard. “Our complex mixtures of cannabis-based TRP ligands were designed to desensitize multiple TRP channels simultaneously, while avoiding the neuronal cytotoxicity and numbness accompanying the harsh capsaicin-based topical pain relievers on the market today that work through hyperactivation of the TRPV1 channel in a way that kills TRPV1-containing sensory neurons.”
GBS and their partners in chronic pain research at Chaminade University have focused on the Transient Receptor Potential (TRP) Superfamily ion channels because they are known to be involved in certain types of pain; for example, TRPV1 is the molecular target for capsaicin-based topical pain relievers. Last month, GBS, Chaminade University, and the University of Hawai’i published a paper on the use of cannabinoids for pain in the journal “Channels” showing the potential analgesic effects of cannabinoids by demonstrating that a variety of specific cannabinoids differentially affect the individual pain-sensing receptors in the TRP family. GBS is designing complex mixtures of cannabis-based ingredients based on their ability to regulate pain receptors in the TRP family located in sensory neurons.
About GBS Global Biopharma, Inc.
GBS Global Biopharma Inc. is a cannabinoid medicine development company located in Ottawa, Canada. Cannabinoid medicine is new science featuring 480+ active ingredients modulating GPCR and Ionotropic receptors involved in many disease conditions and notably those with no treatment or related to opioid addiction. GBS Global proprietary HTS/in Silico platform generates APIs for medical cannabis, nutraceutical supplement and prescription drug markets. The company currently has Rx programs in late pre-clinical and OTC programs at the formulation stage. GBS is working with nanotech time release and rapid dissolve technology for effective oral delivery of their formulations.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
States Where Only CBD Oil Is Legal
That's a whopping 33 states where, operational or otherwise, some form of marijuana is now legal. Add those up with the 3 states where it is completely illegal, and you're left with 13 states.
The laws in these 14 states can vary widely, but to differing degrees, medical cannabidiol can be allowed for legal use there. Many of these states have very strict rules for who can and cannot get approved for CBD based on what medical condition they have the severity of it.
Here are the 14 states with some form of legal medical CBD and what the requirements are, per the National Organization for the Reform of Marijuana Laws (NORML):
In Alabama, the only access to legal CBD is either by being part of a state-sponsored clinical trial, or having a debilitating medical condition for which they are currently under treatment. The access via debilitating medical conditions is also known as Leni's Law.
In Georgia, CBD oil can legally be prescribed to patients with over a dozen medical conditions, including cancer, multiple sclerosis, Parkinson's disease and seizure disorders. The legal limit a patient can have is 20 ounces of marijuana oil with no more than 5% THC, and the CBD amount must be equal to or greater than the THC.
Earlier in 2018, Indiana passed a law that made it legal to manufacture, sell in retail, possess and use CBD oil provided it had no more than 0.3% THC content in it. This was a major expansion of the legality of CBD, no longer requiring Indiana citizens to be on a patient registry to buy CBD oil.
The Department of Public Health in Iowa allows for limited amounts of CBD oil for patients suffering from several medical conditions. This includes HIV/AIDS, cancer, ALS and seizures. Five dispensaries opened very recently in Iowa. This oil can be found in creams, capsules and more.
In 2018, Kansas passed a law that exempted CBD products from the state's criminal code regarding marijuana. This allows for adults to legally purchase and possess CBD products as long as they contain 0% THC.
Kentucky has laws that allow for state-sponsored cultivation of hemp, which can be used to make CBD oil.
Mississippi made it legal for patients with severe epilepsy to use products high in CBD as long as they were low in THC in 2014. The cannabis extract must have more than 15% CBD, but no more than 0.5% THC, and must be done by or under the supervision of a licensed physician.
The law in North Carolina also only makes CBD legal for patients with intractable epilepsy. The CBD for this is made from hemp extract.
South Carolina legalized CBD for those suffering from severe epilepsy disorders (including Dravet Syndrome, the condition Epidiolex was created to treat). The cannabis extract for must have extremely trace amounts of THC.
The state of Tennessee considers CBD made from hemp extract, not marijuana, to be legal. CBD is also able to be prescribed to patients with intractable epilepsy if it contains trace amounts (no more than nine-tenths of one percent) of THC
The CBD law in Texas also makes an exception for intractable epilepsy patients. This went into law in 2015, and the extract must contain over 10% CBD and no more than 0.5% THC.
Virginia recently expanded legal CBD use when Governor Ralph Northram signed into law a bill that legalized CBD oil for any condition diagnosed by a licensed doctor or practitioner.
CBD has been legal as a treatment for seizure disorders in Wisconsin since 2014, and in 2017 the Senate expanded its legality to be used as treatment for any medical condition a doctor recommended it for.
Wyoming has a particularly narrow law for CBD oil. It is only legal for patients with epilepsy that has not responded to other treatments. Neurologists have to give the state's Department of Health a statement about how the patient needs and would benefit from the CBD, made from hemp extract, and then the patient may be able to receive a card that allows them to receive cannabis with high concentrations of CBD and trace amounts of THC.
FDA Warns CBD May Overpromise and Underdeliver
Written by Christopher Curley on August 1, 2019 New
The definition of a ‘drug’
But the FDA warning spotlights an ongoing issue about CBD products: Many claims about CBD-based treatments are unproven.
CBD may well have genuine applications as a medicine — and the scientific research that’s available has largely pointed in that direction, with at least one CBD-derived medicine approved for the treatment of seizuresTrusted Source, for instance.
But for other conditions, there isn’t a lot of evidence proving CBD can be an effective treatment.
https://www.healthline.com/health-news/beware-fake-cbd-claims
No longer a dietary supplement
One of the sticking points of the most recent warning was how the manufacturer’s claims, “establish the intended use of your products as drugs.”
“The FDA does not allow manufacturers of dietary supplements to make any claims with regard to safety or efficacy of their supplements, since each individual manufacturer has not conducted studies,” Brian Prather, a registered pharmacist at Bedford Wellness Pharmacy in Michigan, which sells CBD products, told Healthline.
While you may have seen CBD being marketed in everything from ice cream to hamburgers, the agency pumped the brakes on the use of CBD in food products in June 2019.
They did this because it’s been approved for use in a specific drug and therefore, it cannot be used as a food additive.
“In addition, the FDA does not consider isolated CBD extract to meet the definition of a dietary supplement, so any company promoting their product as CBD — rather than hemp extract — could be subject to FDA action,” Prather explained.
Regarding “hemp extract,” CBD can also be extracted from hemp, an extremely low-THC cannabis which isn’t a federally scheduled drug. And, according to the agency’s definitionsTrusted Source of what is and isn’t a dietary supplement, “hemp extract” may not fall under the same regulatory requirements as CBD extracted from marijuana, which are cannabis plants with higher concentrations of THC.
Hemp plants are cannabis plants with less than 0.3 percent THC. These plants are no longer defined as marijuana under the Controlled Substances Act.
Now with FDA regulations changing, some companies are giving their hemp-derived CBD a new name.
“That’s why we’ve seen a sharp increase in the number of companies promoting their ‘broad-spectrum hemp extract’ to avoid FDA sanctions,” Prather said. “But whether you’re making CBD, hemp extract, or vitamin C, FDA rules strictly prohibit marketing of supplements for specific disease states or medical conditions.”
What the science says
While CBD products have proliferated and experts agree there seems to be little direct risk to using CBD, consumers should know that the science still has a long way to go, according to Dr. Morton Tavel, a clinical professor emeritus of medicine at Indiana University School of Medicine.
“Companies currently involved in the CBD market were hopeful that the FDA would eventually place CBD in the category of food additives called ‘generally recognized as safe,’ but here I must dissent, for until adequate research is performed, this product should be confined to prescription-only status until its safety and efficacy are clearly established,” he said.
“Where I think real science comes in is trying to determine what CBD actually is doing in the body, what it actually is binding to, what it is signaling through, and going at it from a very scientific point of view [to] determine what are objective viable claims,” Matthew Halpert, PhD, researcher and faculty in the department of pathology and immunology at Baylor College of Medicine told Healthline.
Halpert pointed out there are aspects of CBD that appear to be beneficial.
“But there’s clearly just a lot more research that needs to happen,” Halpert said. “And at some point, we’re going to have to move toward hard, placebo-controlled trials to really start making definitive claims.”
In the meantime, he said, one of the major problems is that we don’t understand what a good or standard “dose” of CBD is.
“For some reason that I do not fully understand, the CBD field, instead of talking about dose per serving, people advertise how many milligrams they have in the bottle — as if that means anything,” he said. “There’s this race between companies and people to just take more and more CBD.”
“The thinking seems to be that if taking some is good, then more is better,” he said. “Which is definitely not true. That’s not how biology works.”
Florida law is hazy, but CBD’s popularity is clear at inaugural Miami Beach trade show
BY SAMANTHA J. GROSS AUGUST 02, 2019 07:24 PM
Logan Stull, sales director for Tampa-based Docs Healthy Hemp, said officials at his company “really like” the idea of agencies like the FDA and the state cracking down on non-compliant companies for competitions’ sake.
“A lot of companies don’t pay to get their stuff tested,” he said. “This will weed those people out.”
https://amp.miamiherald.com/news/health-care/article233258709.html
Someone on the Y mentioned a Cannabis company called “Plus Products “ They have a Trademark ™? on Plus for State of California purposes, but is has not applied to USPTO. They incorporated in December 2018. In my opinion they will have to change their name because of confusion. This is another reason for the New Harvest trademark in my opinion. Wolf
https://www.profitconfidential.com/stock/plus-products-inc-stock/plus-products-inc-cannabis-edibles-company/
https://globenewswire.com/news-release/2019/06/06/1865224/0/en/Plus-Products-Acquires-Option-to-Purchase-California-Based-Oil-Manufacturer.html
https://www.newcannabisventures.com/plus-cannabis-infused-products/
Another big hit From Brevin at the Y. Wolf
https://www.benzinga.com/node/14193379
Thanks to Brevin from CVSY. Wolf
Both vitamins and CBD are surging wellness markets.
https://finance.yahoo.com/news/state-cbd-regulation-clear-rules-171034264.html
The U.S. dietary supplement market had a value of $124.8 billion in 2018, according to the market research company Reports and Data, while the U.S. CBD market could reach $16 billion by 2025.
Both sectors are complicated from a regulatory standpoint, and the issue is long-simmering in the vitamin space.
The Letter Of The Law
Dr. Duffy MacKay, the senior vice president of scientific and regulatory affairs at the CBD company CV Sciences, said the Dietary Supplement Health and Education Act of 1994, or DHSEA, gave the FDA authority to regulate vitamins as dietary supplements.
CBD does not fall into this category, MacKay said.
"[The] FDA has a first-to-market policy that says that if an 'article' has been already researched for a potential future drug use, then it can’t be sold as a dietary supplement. This is intended to protect drug research investments."
The FDA's expectations for supplements are clear, he said.
Yet the DSHEA limits a manufacturer from claiming it can prevent or treat diseases, but it does allow for brands to say a product can support some bodily functions and systems.
"If this distinction is too subtle for anyone but a company lawyer or a FDA regulator to understand, that is the point," according to a a 2009 SF Gate article.
"The purpose of DSHEA was to allow supplement-makers to market the health benefits of their products, with or without scientific proof."
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15
Two Takes On CBD Regulations
The issue appears to be a point of concern for major brands like CVS Health Corp (NYSE: CVS).
The company announced in May that it would test unregulated vitamins and diet supplements across 11 categories for safety and label accuracy in all its stores.
With the CBD market in a growth phase, concerns linger over a market that once suffered from scores of mislabeled products.
Jay Hartenbach, CEO of the CBD brand Medterra, said a lack of clarity from the FDA makes it difficult to understand how CBD "can exist as a dietary supplement," leading to reluctance on the part of retailers.
"With that being said, the FDA has committed to working quickly in establishing guidelines and to date has only sought to stop CBD companies from making exaggerated health claims."
The lack of regulations in place today could adversely impact consumer safety, said Calloway Cook, the founder of supplement creator Illuminate Labs.
"A company could put out a harmful product on the market and there is no regulatory mechanism to catch it before it causes harm."
MacKay disagrees.
“To legally sell hemp-derived CBD for ingestion as a non-drug across state lines, then you are responsible for following all of the FDA regulations for either food additives or dietary ingredients.”
The regulations are designed to ensure that finished botanical extracts are safe; tested for purity and potency; and free of harmful contaminants, he said.
The FDA is working on a process to allow CBD sales as a supplement while also serving as a prescription drug, MacKay said.
"The likely outcome is that FDA will define a dividing line between hemp extracts with CBD, as dietary ingredients, which differentiates the ingredient in composition from the prescription-isolated CBD."
Cook said both markets will be regulated within the next 10 years.
“With improvements in technology, it's easier to set up a logistics system where manufacturers and retailers can test, audit and submit results for clearance to the appropriate regulatory agency.”
Related Links:
Cowen: CBD Market Could Reach B By 2025
Thank you Brevin at CVSY. Wolf
Who’s who: CBD and hemp companies shaping the category
BY NORA CALEY
August 2, 2019
The demand most definitely is there. One study, in fact, said that more than 70% of consumers would purchase products infused with CBD or hemp if given the opportunity. Another said that more than half of shoppers simply are shocked that they cannot purchase these products in the store of their choice now, mostly because many retailers still are hesitant to get involved in the category, awaiting more clarification from the Food and Drug Administration.
https://www.drugstorenews.com/otc/whos-who-cbd-and-hemp-companies-shaping-the-category/
Just for comparison. Elixinol is Down from its high of $4.25 per share to $2.05 today. They are getting hit harder than CVSI ever did. A friend of a friend buys the 4 ounce bottle. He claims it gives him a opiated feeling. Possibly larger doses is what the studies are showing in their hypothesis that cbd can be used to get opioid attics off their addiction. Imo Wolf
https://elixinol.com/product/hemp-oil-drops-3600mg-cbd-natural/
Thank you Mark. CBD products from CVSI will hopefully be next on their agenda through McLane Distributors. Imo Wolf
LOS ANGELES— The vertically integrated hemp and CBD product manufacturer, Natural Hemp Company is pleased to introduce its first brand, Day One CBD Sparkling Water (DayOneCBD.com). Day One makes its debut at USA CBD Expo in Miami this week. The flavored sparkling water will be available for purchase at a variety of retail locations nationwide and via dayonecbd.com starting August 1.
“Day One is a perfectly balanced sparkling water that is infused with 20mg of Broad-Spectrum CBD with a splash of lemon fruit juice. We only use all-natural ingredients and our waters have zero calories, zero carbs, and no added sweeteners,” says Chris Clifford, CEO of Natural Hemp Company, the parent company of Day One. “Day One is an extremely dynamic beverage that you can enjoy anytime, whether you are living your best life or recovering from it.”
CBD is non-intoxicating and is legal throughout the United States. CBD is a hemp-based extract adaptogen with a number of potential health benefits, including increased energy levels, pain relief, improved focus, and anxiety relief. While CBD is effective in inhalable and edible forms, CBD-infused water is much easier for the body to absorb, making for a more effective, hydrating, and faster-acting experience.
https://www.bevnet.com/news/2019/day-one-cbd-sparkling-water-set-to-launch
Day One is expected to be sold nationwide in select 7-Elevens, Natural Foods stores and big-box retailers. Day One is optimal for the health and fitness industry and is the perfect beverage at local gyms and commercial studios. Creative and tech-based companies that require extreme focus and creativity—and are high-stress environments—will also benefit from Day One.
Day One currently offers its sparkling CBD water in lemon and will introduce additional flavors later this year. Day One will be supported in the market by an integrated 360 media and marketing campaign, including social media marketing, event sponsorships, brand collaborations, and pop-up shops.
For additional information, please visit DayOneCBD.com.
About Natural Hemp Company
From Food and Beverage to Wellness and Beauty, Natural Hemp Company’s mission is to provide our customers with convenient, high-quality hemp and CBD products. Vertical integration creates a transparent and consistent supply chain and the ability to offer consumer-friendly prices, positioning Natural Hemp Company as a strong retail partner.
CVSI profitability A Plus you understand. Ahooooooo Wolf
Bloomberg) -- Aphria Inc. became the first major Canadian cannabis company to report a net profit, sending its U.S. shares up 33% in pre-market trading Friday.
The Leamington, Ontario-based pot producer said Thursday it earned C$15.8 million ($12 million) in the quarter ended May 31 on revenue of C$129 million. The revenue figure beat the highest analyst estimate, and was up 75% from the prior quarter.
The results are a remarkable shift from last quarter, when Aphria reported a significant drop in gross margin, revenue that missed expectations and a C$50 million writedown on its Latin American assets.
“In the context of poor sector sentiment, profitability becoming an increasing focus, and guidance scarce, this print is very reassuring and supports our conviction in the name,” Jefferies analyst Ryan Tomkins wrote in a note. He’s among 9 analysts carrying a buy-equivalent rating on the stock. “Names who can show a route to profitability (or are there now) have the greatest likelihood attracting near term investor interest.”
Key Insights
Revenue from recreational cannabis sales was C$18.5 million, up 158% from the prior quarter, on 5,574 kilograms of cannabis soldIt also cost Aphria less to produce pot, with cash cost per gram of dried cannabis falling to C$1.35 from C$1.48Aphria said it expects to generate net revenue of C$650 million to C$700 million in fiscal 2020, which ends May 31, and adjusted earnings before interest, taxes, depreciation and amortization of C$88 million to C$95 million. Analysts expected revenue of C$701 million and Ebitda of C$46 million
Thank you Anonymous from the CVSY. Wolf
RESEARCHERS DISCOVER HOW CANNABIS COMPOUNDS 30 TIMES MORE POWERFUL THAN ASPIRIN ARE CREATED
July 31, 2019
Researchers uncover how the cannabis plant creates pain-relieving molecules with the potential to replace aspirin as “ideal painkillers,” according to a new study.
A group of Canadian researchers has released a new study uncovering how cannabis molecules can be used as a natural painkiller, with the potential to replace highly addictive opioids.
“There’s clearly a need to develop alternatives for relief of acute and chronic pain that go beyond opioids,” said Professor Tariq Akhtar, co-author of the study. “These molecules are non-psychoactive and they target the inflammation at the source, making them ideal painkillers.”
Research conducted in 1985 first identified and revealed the power of two cannabis molecules, which displayed anti-inflammatory activity up to thirty times as powerful as that of aspirin. However, due to cannabis prohibition and strict regulations, research at the time was halted.
After Canada ended its prohibition on cannabis last year, Canadian researchers from the Department of Molecular and Cellular Biology at the University of Guelph sought out to understand how the cannflavins, known as flavonoids, were created.
“If you know what you’re looking for, one can bring genes to life, so to speak, and piece together how molecules like cannflavins A and B are assembled,” Akhtar stated.
Using classical biochemistry techniques the team uncovered what was required to form the flavonoids cannflavin A and B, which display anti-inflammatory activity more effective gram-for-gram than aspirin. The Cannflavins target pain by reducing inflammation. This is a different approach from opioids which blocks pain receptors in the brain.
Researchers say more work is needed to create the pain-relieving molecules at a larger scale.
“The problem with these molecules is they are present in cannabis at such low levels, it’s not feasible to try to engineer the cannabis plant to create more of these substances,” co-author Steven Rothstein stated. “We are now working to develop a biological system to create these molecules, which would give us the opportunity to engineer large quantities.”
The study’s findings are to be published in the August edition of Phytochemistry under the title, “Biosynthesis of cannflavins A and B from Cannabis sativa L.”
Cannabis as a Substitute for Opioids?
The Canadian study adds to a growing body of evidence suggesting cannabis may be able to replace opioids as a safer, non-addictive pain reliever. In a recent study published in Drug and Alcohol Dependence, researchers examined prescriptions of Medicaid enrollees from 2010-2017.
The data showed that in 2015, legalized recreational marijuana was associated with a 32 percent drop in the number of opioid prescriptions, a 30 percent decrease in opioid doses, and a 31 percent reduction in spending on Schedule III opioids. Several other studies have had similar results.
Research published in a University of Alabama Legal Studies Research Paper found that recreational and medical marijuana legalization was associated with a 6.9 percent reduction in opioid prescriptions in states with dual marijuana legalization, and a 6.1 percent drop in states with only medical marijuana legalization.
Not only are researchers uncovering a decline in reported use of opioids with legal marijuana access, but a recent study also revealed a drop in the percentages of opioid-related overdoses in U.S. counties with medical marijuana dispensaries. The results from that study found a 6 to 8 percent drop in opioid-related deaths and a 10 percent decrease in heroin overdoses resulting in death.
More Cannabis News and Research
To keep up with the latest news in cannabis research, politics, and business check out our news page.
POST BY E.I. HILLIN
View More
LATEST NEWS
Marijuana effects on sex
RESEARCH SUGGESTS CANNABIS IMPROVES SEXUAL SATISFACTION FOR MEN AND WOMEN
View More
How marijuana legalization effects alcohol consumption
NEW STUDY: AS MARIJUANA IS LEGALIZED, INTEREST IN ALCOHOL DROPS
View More
seniors attitudes on marijuana
MORE SENIOR ADULTS FIND THE USE OF MEDICAL MARIJUANA ACCEPTABLE, STUDY SHOWS
View More
Read More Cannabis News
July 24, 2019
E.I. Hillin
Scientific Research
LATEST POSTS
Research Suggests Cannabis Improves Sexual Satisfaction For Men And Women
Top 10 Cannabis Policy Wins For 2019
Researchers Discover How Cannabis Compounds 30 Times More Powerful Than Aspirin are Created
New Jersey’s Medical Marijuana Program Has Tripled in Size
New York Decriminalizes Marijuana Possession
Enter your email below
for the latest updates from Medical Marijuana, Inc.
Follow us on social networks
Editorial Team
Jeffrey Stamberger
DIGITAL CONTENT WRITER
Eve Ripley
DIGITAL CONTENT WRITER
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Food and Drug Admistration (FDA) Disclosure
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the medicalmarijuanainc.com website. Links to any informational websites are provided solely as a service to our users.
The link provides additional information that may be useful or interesting and has no aliation to the promotion, sale and distribution of Medical Marijuana Inc. products. The link does not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.
* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.
Privacy Policy
© 2019 Medical Marijuana, Inc. All Rights Reserved.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our a Privacy Policy.
AGREE
Sumo
Open Share70
https://news.medicalmarijuanainc.com/researchers-discover-how-cannabis-compounds-30-times-more-powerful-than-aspirin-are-created/
CBD Ohio. Thank you Joseph at the Y. Wolf
Boardman Ohio. Suburb of Youngstown. Home of Cleveland Browns former QB Bernie Kosar and Hackers.
CBD store opening at Southern Park Mall
LOCAL NEWS
Tri-Health will open its first store in Boardman on Saturday
Posted: Aug 1, 2019 / 10:00 PM EDT / Updated: Aug 1, 2019 / 10:41 PM EDT
BOARDMAN, Ohio (WKBN) – Earlier this week, Ohio Gov. Mike DeWine made it legal to sell CBD products in the state. Now, a company with local ties plans to open up shop in Boardman.
Tri-Health will open its first store in the area on Saturday.
It will be located near the food court at the Southern Park Mall.
The store is owned by Paul Kaldy, a Brookfield graduate who operates two CBD stores in Tennessee along with his wife.
The Southern Park Mall location will offer oils, edibles and other products.
You do not need a prescription to purchase CBD products.
https://www.wkbn.com/news/local-news/cbd-store-opening-at-southern-park-mall/
CBD Hacker Ranks the 10 Best CBD Gummies for 2019 (With Lab Results)
May 8, 2019
BOARDMAN, Ohio (PRWEB)
May 08, 2019
CBD Hacker, the definitive guide to the CBD industry, has named their 10 Best CBD Gummies for 2019. The list is the result of hands-on evaluations of gummy products from 26 of the leading CBD producers, along with a few up-and-coming brands.
The full ranking includes gummy products from the following CBD companies:
CBDistillery – Denver, Colorado
cbdMD – Charlotte, North Carolina
Hemplucid – Orem, Utah
Infinite CBD – Lakewood, Colorado
Koi CBD – Norwalk, California
Lord Jones – Los Angeles, California
PlusCBD Oil – San Diego, California
Relive Everyday – Highspire, Pennsylvania
Steve’s Goods – Longmont, Colorado
Sunday Scaries – San Diego, California
http://classifieds.usatoday.com/press/cbd-hacker-ranks-the-10-best-cbd-gummies-for-2019-with-lab-results/
CBD Iowa Kroger’s has no stores in Iowa. Wolf
MedPharm Iowa concerned about future of state's patients, CBD legislation
KCCI Updated: 9:39 PM CDT Aug 1, 2019
DES MOINES, Iowa —
Advocates for medical cannabis in Iowa are trying to open up CBD, or cannabidiol, to patients with a broader range of medical conditions.
CBD sales became legal late last year. While CBD is found in products such as marijuana and hemp, it does not have THC, the psychoactive element.
https://www.kcci.com/article/medpharm-iowa-concerned-about-future-of-states-patients-cbd-legislation/28583565
MedPharm Iowa, a dispensary, said it’s had approximately 6,000 patient transactions at its locations since the program launched late last year.
“There is really no time left,” to change Iowa's laws regarding CBD use, said Lucas Nelson, MedPharm Iowa's general manager.
Nelson gave this warning at a news conference Thursday unveiling the company’s new vaporizing products and giving an update on the company’s progress since CBD sales became legal.
He claims the big threat comes from the other side of the Mississippi River. Illinois passed a bill allowing recreational marijuana starting in 2020. It allows anyone 21 or older to purchase marijuana.
“Patients have told us they’ll be leaving our program to go over to Illinois despite some of the risks,” Nelson said.
The risk being marijuana will still remain illegal in Iowa.
He said Gov. Kim Reynolds’ veto of a bill loosening restrictions on CBD means Iowa’s current program could be a lot less attractive to Iowans needing treatment. Those Iowans might simply drive over the border.
Nelson worries it will put MedPharm and the program in jeopardy.
“I worry that what it will ultimately result in is no medical cannabis available for patients across the entire state,” Nelson said.
He said the company is looking ahead to Friday when the state’s CBD board will meet to consider the company’s petitions to add three qualifying conditions: PTSD, opioid dependency and “severe or chronic” pain.
“We’re really going to encourage the board and thereby Gov. Reynolds and the legislators to step up and hear from patients,” Nelson said.
Thank you Brevin
https://www.marijuanamoment.net/lawmakers-push-federal-agencies-to-free-up-the-cbd-industry/
Lawmakers Push Federal Agencies To Free Up The CBD IndustryPublished 1 hour ago on August 1, 2019 By Kyle Jaeger
A group of lawmakers sent a letter to the heads of the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) this week, describing the economic potential of the CBD market and encouraging the development of regulations for the compound.
The letter, led by Rep. Antonio Delgado (D-NY), states that the passage of the 2018 Farm Bill, which federally legalized hemp and its derivatives such as CBD, “ushered in the potential for a new agricultural industry that will impact textiles, paper, pharmaceuticals, dietary supplements, and countless other consumer products.”
Delgado, who among other signees sits on the House Small Business Committee, added that the “legal cannabis industry provides an opportunity for small firms to the lead the way by fueling local economies and creating new jobs.” The panel held a hearing last month to address opportunities and challenges for cannabis businesses under the federal framework of prohibition.
Committee Chair Nydia Velazquez (D-NY), who introduced legislation this week that would provide marijuana businesses with access to insurance coverage, as well as Reps. Dwight Evans (D-PA), Adriano Espaillat (D-NY) and Jared Golden (D-ME) also signed the letter.
“Farmers around the country are eager to adopt a new exciting crop and are enthusiastically awaiting the establishment of a regulatory framework from the United States Department of Agriculture (USDA),” the group wrote. “Businesses are ready to capitalize on the growing consumer demand for hemp and hemp-derived products, such as cannabidiol (CBD), yet the FDA’s lack of clarity has caused confusion for farmers, businesses, and consumers.”
USDA and FDA have faced pressure to develop regulations for the hemp industry since the farm bill’s passage. FDA said last month that it is “expediting” its rulemaking process and will issue a status update on the agency’s progress by early fall. USDA, meanwhile, said that regulations for legal hemp cultivation will be released ahead of the 2020 planting season.
The lawmakers said that “regulatory uncertainty is currently stifling the potential growth of hemp businesses.”
While former FDA Commissioner Scott Gottlieb said that developing regulations that would allow for CBD to be marketed in food or as dietary supplements could take years without congressional action, the group noted that such products are already being sold “in coffee shops, cocktail bars, restaurants, grocery stores, gas stations, massage parlors, fitness centers, pet stores, and health stores.”
“This business development has occurred largely outside of any well-defined or strictly enforced regulatory regime,” they wrote. “Regulations are needed to address the production, sale, quality, testing, labeling, and marketing hemp-derived products such as CBD.”
“Businesses making unfounded health claims, not otherwise permitted for food or dietary supplements, should certainly not be making these claims about hemp-derived products, and we appreciate the work that the FDA has done to address these issues in the marketplace. But more work is needed. This retail market is far too large to remain unregulated, and the lack of clear regulation can cause a variety of problems around product quality, safety, production, distribution and sales of CBD.”
While the lawmakers said they appreciate FDA’s diligence in ensuring public safety and enforcing rules against unfounded claims made by CBD companies, the industry cannot wait years for the agency to develop regulations.
“We urge the FDA to take prompt and clear regulatory action to clarify the federal rules around the production, sales, and marketing of CBD to support American farmers and entrepreneurs in this growing market, while at the same time providing assurance to consumers that products are not misleading, mislabeled, and are produced using good manufacturing practices,” they wrote. “Now is the time for the FDA to craft benchmark safety and quality standards for the production of hemp-derived products in order to increase consumer satisfaction and confidence as this nascent industry transitions and matures into a legal marketplace.”
The letter states that FDA should release “straightforward enforcement guidance” by September 30 and also “promptly issue an interim final rule, to ensure a regulatory pathway through a permanent final rule, for the use of legally produced CBD as a food additive and a dietary supplement ingredient.”
“Given the current widespread availability of hemp-based products, and the growing consumer demand for CBD, we believe that a clear and efficient regulatory framework is necessary to support American farmers, small businesses, and consumers,” the group wrote. “As increasingly more states legalize marijuana and Federal law recognizes the growth and production of hemp and hemp-derived compounds, it is imperative that agencies provide guidance and reduce barriers for small firms looking to enter this rapidly evolving industry
Proof reading or were you drinking 100 proof Kentucky Bourbon?
The Most Popular Grocery Store in Every State
http://mentalfloss.com/article/74016/most-popular-grocery-store-every-state
https://assets3.thrillist.com/v1/image/1623708
CVSI 5 bagger equals $20.00.
CWBHF 5 bagger equals $100.00.
In the short run which stock appears to be more realistic? The 2 billion dollar market cap stock or the 10 billion dollar market cap stock.
Kentucky There is a retreat from the hyped MJ stocks to the CBD Stocks. If you are in it for the long run, then there is no reason to be concerned about the present. You will just have to wait to unwrap your present in the future you understand. About Trump, China exports Hemp into the USA. Cha Ching.. ahooooooo Wolf
American Companies Seek New Capital North of the Border
On the flipside, Canadian exchanges have presented opportunities to US cannabis companies. Canada is home to the Toronto Stock Exchange (TSE) and the Canadian Securities Exchange (CSE).
The TSE announced in late 2017 that any of its listed companies involved in activities that violate US federal law — namely anything “plant touching” — could be delisted. The most common types of companies that are “plant touching” are cannabis manufacturers, distributors, cultivators, and retailers. “No-touch” companies generally provide a product or service pertaining to the industry but avoid direct involvement with the plant itself – such as fertilizer or packaging providers.
However, the CSE has no such restriction and is a viable and popular alternative for US cannabis companies looking for quick and broad access to liquid capital. US-based MedMen Enterprises, a company with 15 higher-end retail dispensaries in three states, used a reverse merger to list its shares on the CSE back in May. Generally speaking, a reverse merger is the acquisition of an already public company (usually a dormant shell) to avoid the IPO process and cost, to quickly get your company on a public exchange for fundraising through visibility and selling stock. The CSE is jokingly referred to as the "cannabis stock exchange" because nearly 25% of its companies are in cannabis. MedMen, which will trade as MMEN after acquiring oil and gas shell Ladera Ventures Corp., is by far the largest company listed on the CSE and is expected to be the most valuable public US cannabis company to date.
While uncertainty prevails in the United States, US investors interested in the cannabis market could get a piece of the action by investing in Canadian stocks traded in the country in the over-the-counter markets. Most of these stocks can be labeled as penny stocks, so any investment may carry a significantly higher risk component. And, many of the more remote ramifications of doing so remain unknown.
http://www.manzurilaw.com/canada_cannabis_stocks
Should the Wolf place Cubbie on iggy? Cast your vote by clicking on the CVSI ballot and link below. Wolfie
https://www.ebay.com/i/202313389758?chn=ps&var=502288171357&norover=1&mkevt=1&mkrid=711-117182-37290-0&mkcid=2&itemid=502288171357_202313389758&targetid=475515184301&device=m&mktype=pla&googleloc=1027320&campaignid=1669934840&mkgroupid=65058350539&rlsatarget=pla-475515184301&abcId=1139296&merchantid=6296724&gclid=CjwKCAjwm4rqBRBUEiwAwaWjjADEO4dIRVy7ETJFuvbKfv2XwOPEk2NJs7TJ4iZ_1tXQ8RNQV5ICexoC8ZYQAvD_BwE
Patience is not only for doctors you understand. The positive way to accept the bumps in the road. How many CBD companies can say that their products are located in the air conditioned compounds of Kroger’s, CVS, and Wegmans, just to name a few. That’s correct. You can count them on one hand or paw you understand. The USN ESSEX and the 4 Marine sailors who claimed it’s “Easier Said Than Done”
Thanks to Brevin from the Yzoo. Wolf in captivity.
The 9 Best CBD Oils for Pain, Anxiety & Sleep – Weedmaps News
July 31, 2019 by Harry Hall
https://cbdoilheadlines.com/the-9-best-cbd-oils-for-pain-anxiety-sleep-weedmaps-news/
Cannabidiol (CBD) is a health and wellness phenomenon with consumers looking for safe, effective relief from pain, anxiety, and insomnia. And now that barriers to studying and legally accessing CBD are beginning to crumble — cannabis retailers and major drugstores alike sell CBD-based products — there’s more interest in CBD’s therapeutic and medicinal potential than ever.
PlusCBD Oil — CBD Oil Drops
PlusCBD Oil is one of North America’s leading CBD oil brands with high-quality products geared toward a variety of purposes and uses. Plus CBD’s CBD Oil Drops are available in three concentrations, formulated for quick absorption, and are known for being one of the best CBD oils for sleep. A calming peppermint flavor option rounds out the soothing effects of the oil.
Availability: United States
Price: $42-$146
Thanks to Jake from the Y. Wolfie
https://pluscbdoil.com/plus-cbd-oil/pluscbd-oil-new-products-august-2019/
As the leading producer of hemp CBD oil products, we are dedicated to providing a variety of options to help you meet your health goals. We are happy to announce the launch of our new topical, PlusCBD™ Roll-ons and our new PlusCBD™ Oil Unsweetened Drops.
PlusCBD™ Oil Roll-Ons
For High-Intensity Support and Fast Absorption
PlusCBD™ Oil 1oz 300mg UNSWEETENED DROPS
PlusCBD™ Oil Total Plant Complex
Unsweetened & Unflavored Hemp Drops
Here’s an article for some interesting insights. Wolf
CBD Consumer Companies Seeing High Interest, But M&A Future Clouded In Smoke
MergermarketContributor
Markets
By Emily
Jul 22, 2019,12:36 pm
With fewer restrictions than ever, buyers are increasingly curious about the smoking hot CBD-infused consumer products space, but industry experts say remaining regulatory uncertainty and the young age of the category could result in more minority investments than buyouts in the near term.
The inflection point for bringing CBD, or the non-psychoactive part of the cannabis plant, into the mainstream was the passage of the 2018 US Farm Bill last December, which lifted restrictions on selling hemp-derived products across state lines. Since then, CBD-derived beauty, personal care and pet brands, among others, have made their way into national retail chains like Walgreens,
https://www.forbes.com/sites/mergermarket/2019/07/22/cbd-consumer-companies-seeing-high-interest-but-ma-future-clouded-in-smoke/
Michael Lux, a Denver-based Partner at accounting firm Crowe, said he expects strategic minority investments to make up the bulk of CBD’s activity over the next 6-12 months. Although many of the industry’s players are “growing like weeds,” he explained that most are younger than five years old and not ready to explore full exits.
Despite the category’s youth, Lux said interest from consumer packaged goods (CPG) companies has been “very high,” and noted that many of his firm’s CBD-based consumer clients have been approached for strategic investments, as well as research and retail partnerships.
However, one industry banker cautioned that “it will be a bit off” before the market can expect to see acquisitions from traditional CPG groups, particularly for ingestible products like beverages and edibles, since the Food and Drug Administration (FDA) is still working to create a regulatory framework for CBD.
Earlier this week, the FDA announced that it is expediting its effort to create clearer guidelines for CBD, which is believed to have healing property for a range of conditions, including inflammation and anxiety. The department plans to publish a report on its progress by early fall.
In the meantime, companies who operate in the personal care space, with products like CBD-infused topical creams, beauty products and tinctures, are more likely to receive strategic investments, said the banker and a second banker interviewed for this report. Both noted that regulators are more comfortable with non-digestible products, making them a less risky investment.
Canadian cannabis companies, many of which have dual listings on the Canadian and US stock exchanges, are especially likely to invest in US CBD brands in the near term, each of the sources said. They explained that these businesses provide entry into the US market without jeopardizing their US listings, since THC is still federally illegal in the US.
CBD stands for cannabiodil and lacks the psychoactive properties of THC (which stands for tetrahydrocannabinol). Both naturally occur in marijuana/hemp and the farm bill legalized hemp products with only low concentrations of THC.
Seattle-based Lazarus Naturals, which was founded in 2014 and sells CBD-based supplements and personal care products, is one such company. In an April interview with Mergermarket, CEO Sequoia Price-Lazarus said the business has received approaches from publicly-traded Canadian cannabis companies. Though not pursuing a sale, the executive said the company is considering raising up to $20 million in growth capital this year.
Cannabis producer Canopy Growth’s acquisition of London-based natural skincare company This Works in May was more evidence of hemp producers’ interest in the personal care space.
While some financial sponsors, such as Seattle-based Privateer Holdings, were built specifically to invest in CBD and cannabis brands, each of the sources said most US financial sponsors would be barred from investing in the category since most existing funds restrict investments in the space. Lux said he has “heard of a few” sponsors who are interested in raising CBD-friendly funds, but noted that this could take a significant amount of time.
Strategic buyers across a range of industries, including pharmaceuticals, consumer products and food and beverage, are expected to show interest in acquiring CBD brands once FDA regulations become more clear, but in the meantime, activity will be limited to minority investments, particularly from Canada, each of the sources agreed.
“I think people are still trying to figure out where this is going to go,” said Lux. “It’s an industry that didn’t exist 10 years ago and barely existed five years ago, and it sounds cliché, but the sky really is the limit here.”
Someone posted that we can call me,myself,and I, Paranoid?
Sound familiar? CV Sciences is ahead of the game. Wolf
While Aurora Cannabis (ACB) focuses on medical cannabis, it’s also involved in the recreational cannabis market. Aurora Cannabis, Canopy Growth (WEED) (CGC), and Tilray (TLRY) are racing to acquire a piece of the CBD market. However, the process isn’t going to be easy. First, the CBD-derived products need to pass the FDA’s approval process before commercialization. Science will need to back the product. For medical products, the norm is to conduct clinical research to back the products by science. There has been a lot of emphasis on creating products backed by science.
Aurora Cannabis stated that after the clinical research, the “Research data will then be used to drive the development of science-backed, hemp-derived CBD topicals that will be safe and reliable.”
https://marketrealist.com/2019/07/aurora-cannabis-new-clinical-trials-hemp-cbd/
Uncle Bud's Hemp Enters The Vitamin Shoppe
PR Newswire
PR NewswireAugust 1, 2019, 10:00 AM UTC
LEADER IN CBD AND HEMP IS NOW RETAILER'S EXCLUSIVE CBD-BASED PERSONAL CARE LINE IN ALL US STORES
LOS ANGELES, Aug. 1, 2019
https://finance.yahoo.com/news/uncle-buds-hemp-enters-vitamin-100000419.html
https://www.unclebudshemp.com/
NEW HARVEST
For: Body care and toiletry products, namely, skin moisturizers containing CBD
International Class(es): 003 - Primary Class U.S Class(es): 001, 004, 006, 050, 051, 052
Class Status: ACTIVE
Basis: 1(b)
For: Dietary and nutritional supplements, topical balms for analgesic purposes; supplements in capsule form and in liquid form; all of the foregoing containing CBD
International Class(es): 005 - Primary Class U.S Class(es): 006, 018, 044, 046, 051, 052
Class Status: ACTIVE
Basis: 1(b)
https://tsdr.uspto.gov/#caseNumber=88285809&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
Pedro Says South of The Border. South Carolina CBD issues. Wolf
https://www.google.com/search?source=hp&ei=gbBCXdGtH6iQ_QaYxbSwBg&q=pedro+south+of+the+border&oq=pedro+south&gs_l=mobile-gws-wiz-hp.1.0.0l2j46j0l4j0i22i30.2783.8986..10149...1.0..0.192.1486.2j9......0....1.......8..35i39j0i131j46i67j46i131i67j0i67j0i131i67j46i131j46i67i275j46i275j0i20i263.EnP-koRn84c#imgrc=Q7ZpNpe6wHh8QM:
SC attorney general's opinion on raw hemp leaves Upstate CBD store owners confused, fearful
CONOR HUGHES | THE GREENVILLE NEWSUpdated 8:10 a.m. EDT July 30, 2019
“The hemp and CBD trade has since exploded across the state. At least six CBD stores opened in Greenville between October and March, offering products such as CBD oils, edibles, and tinctures, as well as smokable hemp, which has been growing in popularity. Convenience stores, markets, and other vendors have also started to offer the product.”
https://www.greenvilleonline.com/story/news/2019/07/29/confusion-swirls-following-sc-ag-alan-wilson-opinion-raw-hemp-cbd-store-raids/1805084001/
Yesterday within 15 minutes early in the morning volume went from 80,000 to 182,000 seeing the same trend now. Wolf